Oesophageal Probe Evaluation in RF Ablation of Atrial Fibrillation

NCT ID: NCT03246594

Last Updated: 2020-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-03

Study Completion Date

2019-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Trial will evaluate the influence of oesophageal probes in Radio frequency (RF)-ablation of atrial fibrillation regarding oesophageal ulcers after ablation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Trial will evaluate the influence of oesophageal probes in RF-ablation of atrial fibrillation regarding oesophageal complications after ablation.

200 patients will be prospectively randomised into 2 groups. The conventional group will undergo RF-Ablation of atrial fibrillation using an oesophageal probe to measure the temperature during ablation.

In the other group will receive ablation using fixed energy levels (25 Watt) at the posterior left atrial (LA) Wall without an oesophageal probe , All patients will get a gastroscopy for evaluation of oesophageal complications the day after the procedure.

All patients will have a 6 months follow up (FU) in our clinic to be reevaluated for complications (primary endpoint) and rhythm stability. (secondary endpoint)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Esophageal Probe

Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.

Placement of oesophageal probe for temperature measurement

Group Type EXPERIMENTAL

Placement of oesophageal probe for temperature measurement

Intervention Type DEVICE

The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus

No Esophageal Probe

Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.

Intervention: Power limitation of RF generator

Group Type EXPERIMENTAL

Power limitation of RF generator

Intervention Type DEVICE

no probe utilized; Limit the RF Generator Output to 25W

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placement of oesophageal probe for temperature measurement

The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus

Intervention Type DEVICE

Power limitation of RF generator

no probe utilized; Limit the RF Generator Output to 25W

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 12 lead ECG with documented atrial fibrillation
* Indication for RF ablation of atrial fibrillation according to the recent guidelines
* Signed informed consent
* Age 18-85 years

Exclusion Criteria

* Pregnancy or possible pregnancy without negative test within 48h prior to ablation
* Intracardiac thrombus
* Contraindication for oral anticoagulation
* Conditions, that may complicate the positioning of the oesophageal probe
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Heart Center Leipzig - University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Center Leipzig

Leipzig, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Schoene K, Arya A, Grashoff F, Knopp H, Weber A, Lerche M, Konig S, Hilbert S, Kircher S, Bertagnolli L, Dinov B, Hindricks G, Halm U, Zachaus M, Sommer P. Oesophageal Probe Evaluation in Radiofrequency Ablation of Atrial Fibrillation (OPERA): results from a prospective randomized trial. Europace. 2020 Oct 1;22(10):1487-1494. doi: 10.1093/europace/euaa209.

Reference Type DERIVED
PMID: 32820324 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Opera-2016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Esophageal Protection Study: A Multicenter Study
NCT04577859 ACTIVE_NOT_RECRUITING NA
Esophageal Cooling for AF Ablation
NCT03691571 COMPLETED NA
RF Ablation of Atrial Fibrillation
NCT00265629 COMPLETED PHASE1